Tumor Biology

, Volume 35, Issue 8, pp 8193–8199 | Cite as

RETRACTED ARTICLE: Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma

  • Junchao Huang
  • Chengchao Sun
  • Ting Zhang
  • Lei Pan
  • Suqing Wang
  • Qiqiang He
  • Dejia Li
Research Article


The objective of this study is to investigate the expression of HSP90 and the effect of HSP90 inhibitor AUY922 in ACC. The expression of HSP90 was measured in tissue samples from 36 human sporadic adrenocortical tumors by immunohistochemistry, Western blotting, and real-time PCR. The effect of AUY922 was tested on SW13 and H295R cells by evaluating cell viability and apoptosis in vitro. Transwell assay was performed to evaluate the migration of SW13 cells after different concentrations of AUY922. Western blot, real-time PCR, and immunohistochemistry revealed that both HSP90 mRNA and protein were obviously expressed in a higher degree in ACC tissues than ACA tissues and normal adrenal tissues (P < 0.01). Positive staining for HSP90 was found in 15 of 20 ACCs (75.00 %) and in 3 of 16 (18.75 %) ACAs. There existed the significant statistical difference (P < 0.001). AUY922 inhibited the proliferation of ACC cells in a time- and concentration-dependent manner, and increasing apoptosis was observed in tumor cells treated with the HSP90 inhibitor. Finally, migration of SW13 cells was distinctly suppressed after undergoing treatment with AUY922. Our data suggest that the specific HSP90 inhibitor AUY922 can play a therapeutic role in treatment of ACC and, thus, HSP90 could qualify as a promising new target in ACC.


Adrenocortical carcinoma Heat shock protein 90 AUY922 Targeted therapy 


  1. 1.
    Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011;7:323–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Fassnacht M, Allolio B. What is the best approach to an apparently non-metastatic adrenocortical carcinoma? Clin Endocrinol (Oxf). 2010;73:561–5.CrossRefGoogle Scholar
  4. 4.
    Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.CrossRefPubMedGoogle Scholar
  5. 5.
    Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol. 2010;28:401–3.CrossRefGoogle Scholar
  6. 6.
    de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2005;90(3):1819–29.CrossRefPubMedGoogle Scholar
  7. 7.
    de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009;27(7):1108–15.CrossRefPubMedGoogle Scholar
  8. 8.
    Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic hsp90 complex in cancer. Nat Rev Cancer. 2010;10:537–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006;13 Suppl 1:S125–35.CrossRefPubMedGoogle Scholar
  10. 10.
    Weiss LM, Medeiros Jr LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Kouyama R, Hiraishi K, Sugiyama T, et al. Clinicopathological features, biochemical and molecular markers in 5 patients with adrenocortical carcinoma. Endocr J. 2011;58:527–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29:298–302.CrossRefPubMedGoogle Scholar
  13. 13.
    Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27:4619–29.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kirschner LS. The next generation of therapies for adrenocortical cancers. Trends Endocrinol Metab. 2012;23:343–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003;228(2):111–33.CrossRefGoogle Scholar
  16. 16.
    Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Chatterjee M, Jain S, Stuhmer T, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood. 2007;109(2):720–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, et al. A phase ii study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 2012;131:933–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, et al. A phase ii trial of 17-allylamino, 17-demethoxygeldanamycin (17-aag, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. 2012;30:341–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008;68:2850–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 2008;10:R33.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, et al. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res. 2012;32:2551–61.PubMedGoogle Scholar
  23. 23.
    Chatterjee M, Andrulis M, Stuhmer T, Muller E, Hofmann C, Steinbrunn T, et al. The PI3K/Akt signalling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica. 2012;98(7):1132–41.CrossRefPubMedGoogle Scholar
  24. 24.
    Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer. 2012;76:26–31.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Junchao Huang
    • 1
  • Chengchao Sun
    • 2
  • Ting Zhang
    • 2
  • Lei Pan
    • 2
  • Suqing Wang
    • 2
  • Qiqiang He
    • 2
  • Dejia Li
    • 2
  1. 1.Hubei Province Key Laboratory on Cardiovascular, Cerebrovascular, and Metabolic Disorders, School of Nuclear Technology and Chemistry & BiologyHubei University of Science and TechnologyXianningChina
  2. 2.Department of Occupational and Environmental Health, School of Public HealthWuhan UniversityWuhanChina

Personalised recommendations